CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis

[1]  P. Sharma,et al.  Immune checkpoint therapy: Forging ahead , 2022, Science Translational Medicine.

[2]  M. Kanehisa,et al.  KEGG for taxonomy-based analysis of pathways and genomes , 2022, Nucleic Acids Res..

[3]  Zhaohui S. Qin,et al.  UALCAN: An update to the integrated cancer data analysis platform , 2022, Neoplasia.

[4]  T. H. van der Kwast,et al.  The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes. , 2022, Pathology.

[5]  A. Syahir,et al.  CD44: A Multifunctional Mediator of Cancer Progression , 2021, Biomolecules.

[6]  A. Ravaud,et al.  BLADDER CANCER: ESMO CLINICAL PRACTICE GUIDELINE FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP†. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Quan P. Ly,et al.  Pancreatic Tumor Microenvironment Factor Promotes Cancer Stemness via SPP1-CD44 Axis. , 2021, Gastroenterology.

[8]  M. Sinkala,et al.  Cancer Stem Cell Marker CD44 Plays Multiple Key Roles in Human Cancers: Immune Suppression/Evasion, Drug Resistance, Epithelial-Mesenchymal Transition, and Metastasis. , 2021, Omics : a journal of integrative biology.

[9]  V. Marx.  Cancer researchers get a grip on immune cell plasticity , 2021, Nature Methods.

[10]  Zheng Guo,et al.  TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2 , 2020, Oncology reports.

[11]  N. Agarwal,et al.  Advances in bladder cancer biology and therapy , 2020, Nature Reviews Cancer.

[12]  A. Lenis,et al.  Bladder Cancer: A Review. , 2020, JAMA.

[13]  X. Yang,et al.  Traditional Classification and Novel Subtyping Systems for Bladder Cancer , 2020, Frontiers in Oncology.

[14]  P. Sharma,et al.  Dissecting the mechanisms of immune checkpoint therapy , 2020, Nature Reviews Immunology.

[15]  Jian Li,et al.  Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy. , 2019, Cancer letters.

[16]  Minoru Kanehisa,et al.  Toward understanding the origin and evolution of cellular organisms , 2019, Protein science : a publication of the Protein Society.

[17]  Xuhui Huang,et al.  TNF‐&agr; derived from M2 tumor‐associated macrophages promotes epithelial‐mesenchymal transition and cancer stemness through the Wnt/&bgr;‐catenin pathway in SMMC‐7721 hepatocellular carcinoma cells , 2019, Experimental cell research.

[18]  Daniela Matei,et al.  Targeting Cancer Stemness in the Clinic: From Hype to Hope. , 2019, Cell stem cell.

[19]  S. M. Toor,et al.  Immune checkpoint inhibitors: recent progress and potential biomarkers , 2018, Experimental & Molecular Medicine.

[20]  Dandan Sun,et al.  Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas , 2018, Journal of experimental & clinical cancer research : CR.

[21]  J. Meeks,et al.  T1 bladder cancer: current considerations for diagnosis and management , 2018, Nature Reviews Urology.

[22]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[23]  Valentine Wanga,et al.  Covariate‐adjusted Spearman's rank correlation with probability‐scale residuals , 2018, Biometrics.

[24]  S. Pedersen,et al.  The acid-base transport proteins NHE1 and NBCn1 regulate cell cycle progression in human breast cancer cells , 2018, Cell cycle.

[25]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[26]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[27]  H. Matlung,et al.  The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer , 2017, Immunological reviews.

[28]  Doron Lancet,et al.  MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search , 2016, Nucleic Acids Res..

[29]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[30]  Zhijie Kang,et al.  CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer , 2016, Scientific Reports.

[31]  D. Wei,et al.  Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target , 2015, Stem cells translational medicine.

[32]  C. Drake,et al.  Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.

[33]  K. Pienta,et al.  Beyond immune checkpoint blockade: New approaches to targeting host–tumor interactions in prostate cancer: Report from the 2014 Coffey–Holden prostate cancer Academy meeting , 2015, The Prostate.

[34]  Tuan Dinh,et al.  The Health Economics of Bladder Cancer: An Updated Review of the Published Literature , 2014, PharmacoEconomics.

[35]  Emmanuel Barillot,et al.  Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial , 2014, Front. Genet..

[36]  J. Pouysségur,et al.  Disrupting proton dynamics and energy metabolism for cancer therapy , 2013, Nature Reviews Cancer.

[37]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[38]  S. Milstien,et al.  Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy , 2011, Cell Death and Differentiation.

[39]  R. Banerjee,et al.  Intravesical drug delivery: Challenges, current status, opportunities and novel strategies. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[40]  Gary D. Bader,et al.  The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function , 2010, Nucleic Acids Res..

[41]  T. Matozaki,et al.  Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway. , 2009, Trends in cell biology.

[42]  Hema S Bashyam.  CTLA-4: From conflict to clinic , 2007, The Journal of experimental medicine.

[43]  G. Rubin,et al.  Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Goodison,et al.  CD44 cell adhesion molecules. , 1999, Molecular pathology : MP.

[45]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[46]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[47]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..